How to Appeal an EPO Opposition Decision: Step‑by‑step Guide for UK Life‑sciences Patent Holders (2026)

The EPO appeal procedure is the mechanism by which a party dissatisfied with an Opposition Division decision can obtain a review before the Boards of Appeal at the European Patent Office. For UK life‑sciences patent holders, biotech innovators, pharmaceutical companies and their in‑house counsel, that review often determines whether a commercially critical patent survives, is amended or falls away across the entire European patent family. In 2026, the settled operation of tightened admissibility standards under the Rules of Procedure of the Boards of Appeal (RPBA), earlier case management and the normalisation of hybrid oral proceedings mean the margin for procedural error has narrowed considerably.

This guide sets out, step by step, how to file and defend an appeal, the deadlines and documents involved, realistic costs and timelines, and the tactical choices UK patentees must weigh, including when national revocation or settlement is the better route.

Overview, What an EPO appeal is and when to use it

An EPO appeal is a review by the Boards of Appeal of a decision issued by an Opposition Division. Under Article 106 EPC, decisions of the Opposition Division are open to appeal, and the appeal has suspensive effect, the contested decision does not take effect while the appeal is pending. The Boards operate independently of the first‑instance departments. The appeal procedure is primarily a judicial review of the contested decision; the RPBA constrain the extent to which fresh facts, evidence and requests can be introduced at the appeal stage.

This is distinct from national revocation. An EPO appeal produces a centralised outcome affecting the European patent in all designated states, whereas a UK national revocation action before the Patents Court (part of the Business and Property Courts of the High Court) or the Intellectual Property Enterprise Court (IPEC) affects only the UK designation and applies UK validity law. For a biotech patentee facing a revocation decision that threatens a product launch or licensing programme across Europe, the centralised nature of the EPO appeal procedure is usually decisive.

Either the patentee or an opponent may appeal, depending on who was adversely affected at first instance. Immediate tactical considerations for life‑sciences claims include the impact on pending or contemplated infringement proceedings, the effect on freedom‑to‑operate positions, and whether an adverse first‑instance decision undermines a licensing or fundraising narrative.

Callout, When to consider appeal vs surrender/settle: Appeal where the claims retain material commercial value and the grounds of the decision are genuinely arguable. Consider surrender or settlement where the surviving claim scope no longer covers the product, where the prior art is fatal, or where continued proceedings expose the patentee to disproportionate cost and reputational risk.

Eligibility, Who can appeal and which decisions are appealable

Who may file (patentee or opponent)

The right to appeal belongs to any party to the proceedings who is adversely affected by the decision (Article 107 EPC). In opposition proceedings that typically means the patentee whose patent has been revoked or amended against its wishes, or an opponent whose opposition has been rejected or only partially successful. A party that obtained everything it sought at first instance is not adversely affected and cannot appeal. Where multiple opponents participated, each adversely affected opponent may file its own appeal.

Which opposition decisions are appealable

The common outcomes of opposition proceedings are: the opposition is rejected and the patent is maintained as granted; the patent is maintained in amended form; or the patent is revoked. Each of these is a final decision of the Opposition Division and is appealable under Article 106 EPC by a party adversely affected. An interlocutory decision maintaining a patent in amended form is separately appealable. The critical constraint is time: under Article 108 EPC the Notice of Appeal must be filed within two months of notification of the decision, and the Statement of Grounds within four months of notification. These deadlines are strict and, in practice, non‑extendable.

Step‑by‑Step: How to appeal an EPO opposition decision

The following numbered steps form the procedural backbone of the EPO appeal procedure. Each includes the applicable deadline, the practical action required, and, where relevant, an expert tip drawn from Board of Appeal advocacy in life‑sciences matters.

1. Step 1, Decide to appeal: tactical checklist

   Before any deadline runs, assess the commercial triggers. Does the maintained or revoked claim scope still cover the marketed or pipeline product? Is there parallel litigation in the UK or elsewhere that the appeal outcome would influence? Are the Opposition Division’s reasons on novelty, inventive step or sufficiency vulnerable to reasoned challenge? Where the answer to these is negative, early settlement or surrender may preserve resources. Where the claims retain value and the decision is arguable, proceed. Estimated duration: decision to be taken well within the two‑month window, ideally within two to three weeks of notification.

2. Step 2, File Notice of Appeal (two‑month deadline)

   Under Article 108 EPC, the Notice of Appeal must be filed within two months of notification of the decision, and the appeal fee must be paid within the same period. The Notice must identify the contested decision and the appellant. Filing is made electronically through the EPO’s online filing systems. Payment of the appeal fee within the two‑month period is a condition of the appeal being deemed filed, an unpaid or late fee is fatal.

   Expert tip: Diarise the two‑month deadline having regard to the notification rules under the EPC, and confirm the appeal fee has been paid in time. Practitioners often treat the Notice as a formal step and file it early to remove any risk to the appeal fee payment. Estimated duration: 1 day to prepare and file, but must be completed within two months.

3. Step 3, File Statement of Grounds of Appeal (four‑month deadline)

   The Statement of Grounds must be filed within four months of notification of the decision under Article 108 EPC. This is the substantive heart of the appeal. It must set out the legal and factual reasons why the decision should be set aside, addressing each ground on which the Opposition Division relied. Under the RPBA, the Statement of Grounds must contain the appellant’s complete appeal case, all requests, facts, objections, arguments and evidence relied on, because anything held back risks being treated as an amendment to the case and refused admission later.

   Expert tip: Resist the temptation to plead every conceivable ground. In biotech appeals a focused, well‑evidenced attack on the pivotal issue, often inventive step or sufficiency, is more persuasive than a scattergun. Every claim request should be mapped precisely to the prior art and the decision under appeal. Estimated duration: 3–6 weeks of drafting, to be completed within four months.

4. Step 4, Prepare and file response(s) to the other party

   Once the Statement of Grounds is filed, the respondent (opponent or patentee) is invited to reply in writing within a period set by the Board. This exchange defines the battleground for any oral hearing. In life‑sciences matters, prioritise the arguments with the greatest bearing on claim validity, the closest prior art, the plausibility of the technical effect, and the sufficiency of disclosure for the full breadth claimed. Keep auxiliary requests coherent and clearly ranked. Like the appellant, the respondent should present its complete case in the reply. Estimated duration: typically a written window of some months set by the Board.

5. Step 5, Respond to Board communications and interlocutory steps

   The Board may issue procedural communications, request clarification, or set out its preliminary view. The RPBA impose a structured timetable, and parties should respond promptly and precisely. Any interlocutory request, for example to admit a late filing or to consolidate related appeals, must be justified against the RPBA admissibility criteria. Estimated duration: ongoing, following the Board’s timetable.

6. Step 6, Prepare the oral hearing: evidence, experts, claim sets and redrafts

   Where oral proceedings are appointed, they are often where the appeal is decided. Preparation should cover: finalised main and auxiliary claim requests, each annotated against the granted claims and the prior art; expert reports and witness statements, labelled, signed and dated; demonstratives that clarify the technical narrative for the Board; and a considered position on any amendments. Under Article 114 EPC the Board may examine facts of its own motion but may disregard facts and evidence not submitted in due time under Article 114(2) EPC, and the RPBA sharply limit the admission of amendments to a party’s case at the appeal stage.

   Every proposed amendment must be justified as a response to a development in the proceedings, not a fresh line of attack.

   Expert tip: A common cause of lost appeals in biotech is late‑filed evidence being refused admission. Assemble the full evidential case before the Statement of Grounds or response is filed, and treat any post‑filing evidence as at serious risk of exclusion under the RPBA. Estimated duration: 4–8 weeks of intensive preparation ahead of the hearing.

7. Step 7, Oral hearing tactics

   Advocacy before the Boards is concise, technical and issue‑focused. In life‑sciences appeals the decisive questions are usually inventive step (was the claimed effect obvious over the closest prior art?) and sufficiency (is the disclosure enough to work the invention across the claimed breadth?). Prepare to engage directly with the Board’s preliminary opinion, to concede points that cannot be won, and to hold auxiliary requests in reserve in a logical sequence. Where expert evidence is contested, be ready to address the reliability and independence of the expert. Handle any late‑filed evidence, yours or the other side’s, by reference to the RPBA admissibility test.

   Expert tip: Boards reward candour and precision. A patentee who over‑claims at the hearing loses credibility; one who identifies the defensible claim scope early and defends it rigorously is far more likely to secure a favourable maintenance in amended form. Estimated duration: hearings commonly run one day, occasionally longer for complex biotech matters.

8. Step 8, Post‑decision options

   Following the decision, consider whether the Board has remitted the case to the Opposition Division under Article 111 EPC for further prosecution, whether a petition for review by the Enlarged Board of Appeal is available on the narrow grounds permitted under Article 112a EPC, and how the outcome interacts with any parallel national action in the UK. The Board’s decision on the merits is final; a petition for review is confined to specified fundamental procedural defects, not the substantive assessment. Estimated duration: the written decision typically follows the hearing within weeks to a few months.

Step / Who / Duration timeline

Required documents for the EPO appeal procedure

Assembling a complete and correctly formatted set of documents is a precondition for a smooth appeal. Corporate appellants should pay particular attention to authorisation and signature requirements, and to translations where original documents are not in English, French or German.

Admissibility rules for late evidence

The RPBA govern whether evidence, arguments or amended claim requests introduced after the Statement of Grounds or the response will be admitted. The framework operates as a convergent approach: the later a submission is made, the higher the hurdle for its admission. A submission made only at the oral hearing faces the strictest test and is frequently refused. Practitioners should treat the RPBA as requiring the whole case to be presented at the outset, with any later material justified strictly as a proportionate response to a specific new development in the proceedings.

Timeline and deadlines, key dates and practical calendar

Deadline management under the EPO appeal procedure begins from the notification of the decision. The two headline deadlines under Article 108 EPC, two months for the Notice of Appeal and appeal fee, and four months for the Statement of Grounds, are the fixed points around which everything else is planned. Because these periods run from the notification of a single decision, an error in calculating them can be catastrophic.

Practical steps to preserve rights include: recording the notification date immediately on receipt of the decision; setting internal reminders well ahead of both the two‑month and four‑month dates; and confirming appeal fee payment separately from the filing of the Notice. Board discretion to extend these statutory periods is effectively non‑existent, so there is no safety net. Where a party has missed a period despite all due care, re‑establishment of rights under Article 122 EPC may in principle be available in limited circumstances, but it should never be relied upon in planning.

Once the appeal is on foot, the Board sets the procedural rhythm. A preliminary communication indicating the Board’s provisional view often follows in advance of the summons to oral proceedings. The overall time to a decision varies considerably with the Board’s workload, and complex biotech appeals can run for several years from the filing of the appeal. Choosing between the EPO appeal procedure, UK national revocation and settlement is a strategic decision that should account for these timelines, the desired scope of relief and cost exposure.

Costs and fees, what to budget

Budgeting realistically is essential, particularly in biotech appeals where multiple experts and extensive evidence drive costs toward the upper end. The figures below are indicative only; the official appeal fee is set by the EPO and is subject to change, so the current fee schedule should always be checked before filing.

Unlike UK national litigation, in EPO proceedings each party generally bears its own costs; the EPO does not routinely award party‑and‑party costs on the scale seen in the UK courts, although the Board may in defined circumstances order a different apportionment of costs incurred in oral proceedings or the taking of evidence. Separately, the appeal fee may be reimbursed where the appeal is allowed and reimbursement is equitable by reason of a substantial procedural violation, a further reason to confirm the current position on the EPO’s official pages.

What changes in 2026, updates practitioners must know

The most consequential feature shaping the EPO appeal procedure in 2026 is the settled operation of the RPBA in its current form. The convergent approach to admissibility is now firmly embedded in Board practice, and the practical effect is that Boards are markedly less willing to admit new requests, arguments or evidence introduced after the Statement of Grounds. This stricter posture places an even greater premium on front‑loading the case.

Case management is oriented towards focusing the parties, through preliminary opinions, on the decisive issues ahead of the hearing. Hybrid and video oral proceedings have become routine, allowing UK‑based teams to attend by video where appropriate while retaining the option of in‑person advocacy for the most significant matters. The likely practical effect for life‑sciences appellants is that thorough, complete first submissions and disciplined case management engagement matter more than ever; late tactical manoeuvres are increasingly counter‑productive.

Common pitfalls and how to avoid them

Many appeals are lost not on the underlying science but on procedure and presentation. The following red flags should prompt early corrective action, and, in some cases, a reassessment of whether to appeal at all.

• Missing the Article 108 deadlines. Calculate both periods from notification and diarise them the day the decision arrives.
• Unpaid or late appeal fee. Pay the fee separately and early; confirm it has been received within the two‑month window.
• Incomplete Statement of Grounds. Present the entire case, all requests, arguments and evidence, at the outset to avoid RPBA admissibility problems.
• Over‑broad grounds. A focused attack on the pivotal issue usually outperforms a scattergun of weak points.
• Late‑filed evidence. Assemble expert reports and witness statements before filing; late material is frequently refused under the RPBA.
• Weak or partisan expert evidence. Choose credible experts and ensure reports are properly signed and dated.
• Poor claim mapping. Annotate every request against the granted claims and the prior art so the Board can follow the amendments.
• Disorganised auxiliary requests. Rank requests logically and coherently; an unclear hierarchy undermines credibility.
• Ignoring the Board’s preliminary opinion. Engage directly with it rather than repeating the first‑instance arguments.
• Introducing fresh amendments at the hearing. These face the strictest admissibility test and are usually excluded.
• Underestimating cost and timeline. Budget for a multi‑year horizon in complex biotech matters.
• Failing to consider parallel strategy. Assess UK national revocation or settlement alongside the appeal, not as an afterthought.

Conclusion

The EPO appeal procedure remains a pivotal battleground for UK life‑sciences patent holders defending or challenging a European patent after opposition. Success turns less on legal ingenuity at the hearing than on disciplined execution before it: meeting the Article 108 EPC deadlines to the day, front‑loading a complete and well‑evidenced case in the Statement of Grounds, respecting the RPBA admissibility framework, and preparing the oral hearing with focused advocacy and credible expert evidence. With Boards applying strict admissibility standards and focused case management in 2026, the patentees who prevail are those who treat the EPO appeal procedure as a single, carefully planned exercise from notification to decision, while keeping national revocation and settlement options in clear view.

For bespoke appeal strategy, contact us via the author’s Global Law Experts profile.

Sources

1. European Patent Convention (EPC), legal texts
2. Rules of Procedure of the Boards of Appeal (RPBA)
3. EPO, Boards of Appeal
4. EPO, Fees (official fee schedule)
5. EPO, Case law of the Boards of Appeal
6. UK Patents Act 1977 (legislation.gov.uk)